Current trials: T-Cell Non-Hodgkin Lymphoma

ALCL-VBLRecruiting

International collaborative prospective study for children and adolescents with standard-risk ALK-positive anaplastic large-cell lymphoma (ALCL) to evaluate the efficacy of vinblastine (ALCL-VBL)

Anaplastic large cell lymphoma (ALCL) is a malignant disease of the lymphatic system. Although the chances of a cure are good, this requires the use of an intensive combination of chemotherapy drugs. The goal of the ALCL-VBL study is to achieve treatment outcomes at least as good as those of standard therapy using vinblastine alone, while reducing side effects. The drug has already shown good results in cases of recurrent ALCL. Children and adolescents under the age of 18 who have ALK-positive ALCL in the standard-risk group and have not yet received any treatment are eligible to participate in the study.

0–17 years · First line · Phase III

OncoPhysRecruiting

OncoPhys Study: Investigating Physical Activity in Cancer Patients Using Questionnaires, Activity Trackers, and Patients

Physical activity can improve treatment outcomes for cancer patients. However, the accuracy of methods used to measure physical activity can vary greatly. The goal of the OncoPhys study is to compare the results of physical activity measurements obtained using a questionnaire and an activity tracker. Women and men aged 18 and older with lymphoma, pancreatic cancer, or colorectal cancer are eligible to participate in this study.

18 years and older

KILTRecruiting

New Antibody (Lacutamab) for the Treatment of T-Cell Lymphomas

Peripheral T-cell lymphomas (PTCL) are a group of various rare, aggressive lymphomas. The subtypes can vary greatly in their characteristics and treatment. Standard treatment involves chemotherapy; however, in 30% of cases, the therapy is ineffective (refractory) or the disease returns (recurrence). A commonly used treatment in such cases is chemotherapy with gemcitabine and oxaliplatin (GemOx). The goal of the KILT study is to investigate the efficacy and safety of a new antibody (lacutamab) in combination with GemOx compared to GemOx alone. Eligible participants include women and men aged 18 and older with relapsed/refractory PTCL whose tumor cells express at least 1% of the KIR3DL2 protein on their surface and who have received at least one prior course of systemic chemotherapy.

18 years and older · Relapsed / refractory · Phase II

RELATIVITY-069

Combination of drugs already used to treat skin cancer may offer a new treatment option for Hodgkin's and non-Hodgkin's lymphomas

Hodgkin’s and non-Hodgkin’s lymphomas are malignant diseases of the lymphatic system. New treatment options are being sought for cases in which the disease remains active or recurs despite therapy. The goal of the RELATIVITY-069 study is to investigate the safety, tolerability, and efficacy of the combination of the two drugs, relatlimab and nivolumab, which has not yet been studied for this purpose. Patients under the age of 31 with recurrent or uncontrollable Hodgkin lymphoma or non-Hodgkin lymphoma are eligible to participate in this study.

up to 30 years · Relapsed / refractory · Phase I/II

DR-01-ONC-001Recruiting

A new treatment option for malignant blood cancers of T lymphocytes, such as LGL leukemia and cytotoxic lymphomas

Malignant blood cancers involving T lymphocytes are rare; furthermore, aside from standard chemotherapy regimens, there are currently no targeted treatment options available. For this reason, new therapies are being tested in clinical trials. The goal of this study is to evaluate a new drug called DR-01 for efficacy and safety in various T-cell disorders, such as LGL leukemia and cytotoxic lymphomas. The study also aims to determine the optimal dosage. Women and men with a malignant T-cell disorder are eligible to participate, provided they have already received at least one systemic therapy and do not have central nervous system (CNS) involvement.

18 years and older · Relapsed / refractory · Phase I/II

PRT2527-02In preparation

A study of the drug "PRT2527" alone and in combination with zanubrutinib in various refractory and relapsed hematologic diseases

Malignant diseases of the blood and lymphatic system are usually treated with immunochemotherapy. These treatments are often effective. If the disease cannot be controlled by this approach (refractory) or if disease activity resumes (recurrence), the therapy must be intensified. The aim of this study is to investigate the safety and efficacy of the drug “PRT2527” as monotherapy and in combination with the approved drug zanubrutinib. Patients aged 18 and older with aggressive B-cell lymphoma, mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter transformation, or T-cell lymphoma (TCL) are eligible to participate in this study.

18 years and older · Relapsed / refractory · Phase I

Briga-PEDRecruiting

Dose Determination of Brigatinib in Children and Young Adults with ALK-Positive Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

A mutation in anaplastic lymphoma kinase (ALK) can contribute to the development of various cancers. This enzyme is the target of the study drug brigatinib, which is approved for the treatment of ALK-mutated lung tumors in adults. The goal of the Briga-PED study is, first, to determine the optimal dose in young adults and children with tumors harboring an ALKmutation, and second, to evaluate the efficacy and safety of brigatinib in children with anaplastic large cell lymphoma or myofibroblastic tumors, both of which carry an ALK mutation. Children and young adults between the ages of 1 and 25 with anaplastic large cell lymphoma, inflammatory myofibroblastic tumors, or other solid tumors are eligible to participate in this study. The disease must be ALK-positive.

1–25 years · Relapsed / refractory · Phase I/II

GLA-RegisterRecruiting

German Lymphoma Alliance Registry

To improve the treatment of lymph node cancer (lymphomas), there are numerous clinical trials, most of which focus on specific subgroups. The collection of “real-world data” is an additional tool for drawing conclusions about the course of treatment, prognosis, and unmet medical needs based on data from everyday clinical practice. The goal of the GLA registry study is to better understand the course of these diseases and the effectiveness of various treatments in real-world clinical practice. Women and men aged 18 and older with a confirmed diagnosis of malignant lymphoma are eligible to participate, regardless of whether they are currently undergoing treatment or not.

18 years and older

TERZORecruiting

Comparison of Duvelisib with Standard Chemotherapy Using Gemcitabine or Bendamustine in Patients with Recurrent or Treatment-Resistant Nodal T-Cell Lymphoma with a TFH Phenotype

Nodal T-cell lymphomas with the TFH phenotype are rare malignant diseases of the lymphatic system that originate from a specific subpopulation of T cells. To date, they have been treated with chemotherapy. The goal of the TERZO study is to investigate the efficacy and safety of duvelisib compared to chemotherapy with gemcitabine or bendamustine. Patients aged 18 years or older with nodal T-cell lymphoma with a TFH phenotype are eligible to participate in this study if the disease has returned (recurred) after prior treatment or has not responded adequately to treatment (refractory).

18 years and older · Relapsed / refractory · Phase III

Current trials: T-Cell Non-Hodgkin Lymphoma9